
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a licensed securities dealer or registered institution in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your securities in YiChang HEC ChangJiang Pharmaceutical Co., Ltd., you should at once hand this circular, the form of proxy and reply slip to the purchaser or transferee, licensed securities dealer or registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 01558)

**2017 Report of the Board of Directors
2017 Report of the Board of Supervisors
2017 Consolidated Financial Statements
2017 Annual Report
2017 Profits Distribution Plan
Re-appointment of the Auditor of the Company
Proposed Election of Directors of the Second Session of
the Board of Directors
Proposed Election of Shareholder Representative Supervisors of
the Second Session of the Board of Supervisors
General Mandate to Issue Shares
and
Notice of Annual General Meeting**

A letter from the Board of Directors is set out on pages 3 to 12 of this circular.

A notice convening the AGM to be held at the meeting room of the Company, No. 38 Binjiang Road, Yidu, Yichang, Hubei Province, the PRC, at 10:00 a.m. on Friday, 8 June 2018, is set out on pages 13 to 18 of this circular. A form of proxy for use at the AGM is also enclosed. The form of proxy is also published on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk).

Whether or not you intend to attend the AGM, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return the same to the Company's office of the Board of Directors at Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang'an County, Dongguan, Guangdong Province, the PRC (for holders of Domestic Shares) or to the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares). In any event, such form of proxy must be returned no later than 24 hours before the time appointed for the AGM (i.e. before 10:00 a.m. on Thursday, 7 June 2018) or any adjournment thereof. Completion and return of the form of proxy shall not preclude you from attending, and voting in person at the AGM or any adjournment thereof if you so desire.

23 April 2018

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms and expression have the meanings set forth below:

“AGM”	the 2017 annual general meeting of the Company to be convened and held at the meeting room of the Company, No. 38 Binjiang Road, Yidu, Yichang, Hubei Province, the PRC, at 10:00 a.m. on Friday, 8 June 2018
“Articles of Association”	the articles of association of the Company (as amended from time to time)
“Board of Directors”	the board of Directors of the Company
“Board of Supervisors”	the board of Supervisors of the Company
“Company”	YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (宜昌東陽光長江藥業股份有限公司), a company established in the PRC on 11 May 2015 as a joint stock company
“Director(s)”	the director(s) of the Company
“Domestic Share(s)”	issued ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is (are) subscribed for or credited as fully paid in RMB
“Group”	the Company and its subsidiaries
“H Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is (are) listed on the Stock Exchange and is (are) subscribed for and traded in Hong Kong dollars
“HKD”	Hong Kong Dollar, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

DEFINITIONS

“PRC” or “China”	the People’s Republic of China and for the purpose of this circular, excluding Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended and modified from time to time
“Share(s)”	share(s) of the Company
“Shareholder(s)”	the shareholder(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subsidiary(ies)”	has the same meaning ascribed thereto under the Listing Rules
“Supervisor(s)”	the supervisor(s) of the Company
“%”	percentage

LETTER FROM THE BOARD OF DIRECTORS



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 01558)

The Board of Directors:

Executive Directors:

Mr. JIANG Juncai
Mr. WANG Danjin
Mr. CHEN Yangui
Mr. ZHU Qiaohong

*Registered Office and Principal Place
of Business in the PRC:*

No. 38 Binjiang Road
Yidu, Yichang
Hubei Province
the PRC

Non-executive Directors:

Mr. TANG Xinfu (*Chairman*)
Mr. MO Kit

*Principal Place of Business
in Hong Kong:*

18/F, Tesbury Centre
28 Queen's Road East
Wanchai
Hong Kong

Independent Non-executive Directors:

Mr. TANG Jianxin
Mr. FU Hailiang
Mr. LEE Chi Ming

23 April 2018

To the Shareholders

Dear Sir or Madam,

**2017 Report of the Board of Directors
2017 Report of the Board of Supervisors
2017 Consolidated Financial Statements
2017 Annual Report
2017 Profits Distribution Plan
Re-appointment of the Auditor of the Company
Proposed Election of Directors of the Second Session of
the Board of Directors
Proposed Election of Shareholder Representative Supervisors of
the Second Session of the Board of Supervisors
General Mandate to Issue Shares
and
Notice of Annual General Meeting**

LETTER FROM THE BOARD OF DIRECTORS

I. INTRODUCTION

The Company proposes to hold the AGM at 10:00 a.m. on Friday, 8 June 2018 at the meeting room of the Company, No. 38 Binjiang Road, Yidu, Yichang, Hubei Province, the PRC. The notice to convene the AGM is set out on pages 13 to 18 of this circular.

The purpose of this circular is to provide you with information of the resolutions to be proposed at the AGM to enable you to make an informed decision on whether to vote for or against or abstain from voting at those resolutions. Such resolutions and details are set out in the Letter from the Board of Directors.

II. MATTERS TO BE RESOLVED AT THE AGM

ORDINARY RESOLUTIONS

1. Report of the Board of Directors for the year ended 31 December 2017

An ordinary resolution will be proposed at the AGM to approve the report of the Board of Directors for the year ended 31 December 2017, the full text of which is included in the 2017 annual report of the Company to be published at the Company's website and the HKExnews website of the Stock Exchange in due course.

2. Report of the Board of Supervisors for the year ended 31 December 2017

An ordinary resolution will be proposed at the AGM to approve the report of the Board of Supervisors for the year ended 31 December 2017, the full text of which is included in the 2017 annual report of the Company to be published at the Company's website and the HKExnews website of the Stock Exchange in due course.

3. Consolidated financial statements for the year ended 31 December 2017

An ordinary resolution will be proposed at the AGM to approve the consolidated financial statements of the Company for the year ended 31 December 2017, the full text of which is included in the 2017 annual report of the Company to be published at the Company's website and the HKExnews website of the Stock Exchange in due course.

4. 2017 Annual Report

An ordinary resolution will be proposed at the AGM to approve the Company's annual report for 2017, which will be published at the Company's website and the HKExnews website of the Stock Exchange in due course.

LETTER FROM THE BOARD OF DIRECTORS

5. Profits distribution plan and declaration of final dividend for the year ended 31 December 2017

An ordinary resolution will be proposed at the AGM to approve profits distribution plan and declaration of final dividends of the Company for the year ended 31 December 2017.

The Board of Directors proposed to distribute a final dividend of RMB0.30 (tax inclusive) per share for the year ended 31 December 2017 (the “**2017 Final Dividend**”) with an aggregate amount of approximately RMB135.61 million to the Shareholders whose names are listed on the Company’s register of members as at 19 June 2018. The 2017 Final Dividend will be denominated and announced in RMB. The Company will pay dividends in respect of Domestic Shares in RMB and dividends in respect of H Shares in HKD. The actual amount of dividends in respect of H Shares to be paid in HKD to holders of H Shares will be calculated based on the average selling exchange rate as published by the People’s Bank of China within one week prior to and including the date on which the 2017 Final Dividend is approved at the AGM. The 2017 Final Dividend is expected to be distributed on or around 16 July 2018. The 2017 Final Dividend is subject to the approval of Shareholders on the AGM.

Meanwhile, an ordinary resolution of authorizing the Board of Directors to implement the aforementioned distribution plan is proposed at the AGM.

Withholding and Payment of Final Dividend Income Tax

Pursuant to the Enterprise Income Tax Law of the People’s Republic of China (《中華人民共和國企業所得稅法》) and its implementation rules both effective since 1 January 2008, and other relevant provisions, the Company is required to withhold and pay a 10% enterprise income tax when paying the proposed 2017 Final Dividend to non-residential enterprise shareholders listed on the Company’s register of members of H shares. Any H share registered in the name of a non-individual shareholder, such as HKSCC Nominees Limited, other nominees, trustees, organizations or corporates, will be deemed as shares held by a nonresidential enterprise shareholder, and therefore the enterprise income tax on the receivable dividend in respect of such shares will be withheld.

According to the Individual Income Tax Law of China (《中華人民共和國個人所得稅法》) and its implementation provisions, the Notice Concerning Individual Income Tax on the Dividends, Bonuses that Foreign Individuals Obtain from Foreign Invested Enterprises Issued by the Ministry of Finance of Hubei Province (《湖北省地方稅務局關於對外籍個人從外商投資企業取得股息紅利所得徵收個人所得稅問題的公告》), the Notice of the State Administration of Taxation on the Issues Concerning Taxation and Administration of Individual Income Tax After the Repeal of the Document (Guo Shui Fa [1993] No. 045) (Guo Shui Han [2011] No. 348)《國家稅務總局關於國稅發[1993]045號文件廢止後有關個人所得稅徵管問題的通知》(國稅函[2011]348號)) and other laws and regulations, the Company will withhold and pay the personal income tax at the tax rate of 10% generally for individual Shareholders of H shares. For the individual Shareholders of H shares who are citizens of countries or regions that

LETTER FROM THE BOARD OF DIRECTORS

have entered into a tax treaty with the PRC with tax rates higher than 10% but lower than 20%, the Company will withhold the tax at the agreed rates under such treaties. For the individual Shareholders of H shares who are citizens of countries or regions without taxation treaties with the PRC, the Company will withhold the tax at a rate of 20%.

The aforesaid non-residential enterprises and foreign individuals may enjoy the concessionary tax rate in accordance with the relevant provisions of treaties or arrangements for avoidance of double taxation entered into between their country (region) and PRC, and the Announcement No. 60 in 2015 of the State Administration of Taxation: Administrative Measures for Nonresidents to Enjoy the Treatments of Tax Treaties (《非居民納稅人享受稅收協定待遇管理辦法》) (the “**Measures**”) after completing relevant procedures. The aforesaid Shareholders shall provide complete information as required by the Measures to the Company by 25 June 2018. The Company will file tax return to enable the aforesaid shareholders to enjoy the concessionary tax rate stipulated in the Measures. The Company assumes no responsibility and disclaims all liabilities whatsoever in relation to the tax status or tax treatment of the Shareholders of H shares of the Company and for any claims arising from any delay in or inaccurate determination of the tax status or tax treatment of the Shareholders of H shares of the Company or any disputes over the withholding mechanism or arrangements.

6. *Re-appointment of the auditor of the Company*

An ordinary resolution will be proposed at the AGM to approve the re-appointment of KPMG as the auditor of the Company for a term of office ending on the conclusion of the next annual general meeting of the Company, and to authorize the Board of Directors to determine its remuneration.

7. *Proposed election of Directors of the second session of the Board of Directors*

The term of the first session of the Board of Directors shall expire soon. The Board of Directors convened a meeting on 10 April 2018, and considered and approved the following candidates for Directors of the second session of the Board of Directors:

- (1) candidates for executive Directors: Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui, Mr. ZHU Qiaohong and Mr. LI Shuang;
- (2) candidate for non-executive Director: Mr. TANG Xinfu; and
- (3) candidates for independent non-executive Directors: Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming.

LETTER FROM THE BOARD OF DIRECTORS

The Board of Directors also resolved to appoint the members of each of the Board Committees as below, upon the approval of such candidates as Directors by the Shareholders:

- (1) Audit Committee: Mr. TANG Jianxin (Chairman), Mr. TANG Xinfu, Mr. LEE Chi Ming;
- (2) Remuneration and Evaluation Committee: Mr. FU Hailiang (Chairman), Mr. JIANG Juncai, Mr. TANG Jianxin; and
- (3) Nomination Committee: Mr. LEE Chi Ming (Chairman), Mr. ZHU Qiaohong, Mr. FU Hailiang.

According to the Company Law of the PRC and the Articles of Association, all existing Directors shall continue to perform their duties as Directors before the election and formation of the second session of the Board of Directors.

The above candidates for Directors of the second session of the Board of Directors meet the requirements as stipulated in relevant PRC laws, regulations and the Articles of Association, and will be elected as Directors of the second session of the Board of Directors at the AGM. The Board of Directors agreed to submit the above list of candidates for consideration at the AGM.

The Directors of the second session of the Board of Directors will serve for a term of three years. Subject to the approval of those candidates for Directors by the Shareholders, the Company will enter into a service contract with each of them and for a term commencing on the date of their appointments approved by the AGM until the expiration of the second session of the Board. The remuneration of each executive Director will be determined pursuant to the decisions of the general meeting, and with reference to the duty, responsibility and performance of the executive Directors, results of the Group and other factors which may be considered as relevant and appropriate. The non-executive Director will not receive remuneration from the Company. The proposed annual remuneration of Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming for serving as an independent non-executive Director are approximately RMB100,000, RMB100,000 and RMB160,000, respectively, which were determined with reference to their duties and responsibilities within the Company, the Company's remuneration policy and the prevailing market conditions.

The biographical details of the candidates of the Directors for the second session of the Board of Directors are set out in the Appendix I to this circular.

As of the date of the circular, save as disclosed in Appendix I, the candidates for Directors above confirmed that (i) they did not hold any directorship in any other listed companies during the past three years; (ii) they do not hold any other position in the Group; (iii) they have no relationship with any Director, Supervisor, senior management member, substantial shareholder or controlling shareholder of the Company; and (iv) they have not owned any interest as defined in Part XV of the SFO in the shares or underlying shares of the Company.

LETTER FROM THE BOARD OF DIRECTORS

Save as disclosed in Appendix I, the candidates for Directors stated above have no involvement in any matter which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

8. Proposed election of shareholder representative Supervisors of the second session of the Board of Supervisors

The term of the first session of the Board of Supervisors shall expire soon. The Board of Supervisors convened a meeting on 10 April 2018, and considered and approved Ms. HUANG Fangfang and Mr. LUO Zhonghua as the candidates for shareholder representative Supervisors of the second session of the Board of Supervisors. On 10 April 2018, Mr. WANG Shengchao was elected as the employee representative Supervisor of the second session of the Board of Supervisors by the 2018 first meeting of the employee representatives of the Company. The Company will enter into a service contract with Mr. Wang. The term of Mr. Wang serving as the employee representative Supervisor of the second session will be the same as that of the second session of the Board of Supervisors. Re-election may be carried out upon expiration of the tenure of office.

According to the Company Law of the PRC and the Articles of Association, all existing Supervisors shall continue to perform their duties as Supervisors before the election and formation of the second session of the Board of Supervisors.

The above candidates for shareholder representative Supervisors meet the requirements as stipulated in relevant PRC laws, regulations and the Articles of Association, and the Board of Supervisors agreed to submit the above list of candidates for consideration at the AGM.

The Supervisors of the second session of the Board of Supervisors will serve for a term of three years. Subject to the approval of those candidates for shareholder representative Supervisors by the Shareholders, the Company will enter into a service contract with each of them, for a term of commencing on the date of their appointments approved at the AGM until the expiration of the term of the second session of the Board of Supervisors.

Each of the proposed Supervisors of the second session of the Board of Supervisors will not receive any Supervisor's remuneration for serving as the Supervisors during their respective term of office, and will only receive remuneration for their respective position held in the Company, the amounts of which are determined by the management of the Company.

The biographical details of the candidates of the shareholder representative Supervisors and the employee representative Supervisors for the second session of the Board of Supervisors are set out in the Appendix II to this circular.

As of the date of the circular, save as disclosed in Appendix II, the candidates for shareholder representative Supervisors and the employee representative Supervisor mentioned above confirmed that (i) they did not hold any directorship in any other listed companies during the past three years; (ii) they do not hold any other position in the Group; (iii) they have no

LETTER FROM THE BOARD OF DIRECTORS

relationship with any Director, Supervisor, senior management member, substantial shareholder or controlling shareholder of the Company; and (iv) they have not owned any interest as defined in Part XV of the SFO in the shares or underlying shares of the Company.

Save as disclosed in Appendix II, the candidates for shareholder representative Supervisors and the employee representative Supervisor mentioned above have no involvement in any matter which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

SPECIAL RESOLUTION

9. GENERAL MANDATE FOR THE ISSUANCE OF SHARES

A special resolution will be proposed at the AGM to approve the general mandate for the issuance of shares.

To guarantee the flexibility and the rights to handle the issuance of new shares for the Board of Directors, the Company proposed to grant a general mandate to the Board of Directors to allot, issue and deal with the Domestic Shares and H Shares which, each of them, shall not exceed 20% of the respective aggregate number of the Domestic Shares and H Shares in issue of the Company at the date of the passing of this resolution. As at the date of this circular, issued share capital of the Company comprises 226,200,000 Domestic Shares and 225,822,850 H Shares. Upon the passing of the resolution of general mandate to issue Shares, and on the basis that no further Shares are issued before holding the AGM, the Company may issue a maximum of 45,240,000 Domestic Shares and 45,164,570 H Shares.

Details of the general mandate proposed to be granted to the Board of Directors are as follows:

- (1) the Board of Directors be granted an unconditional general mandate to issue, allot and deal with additional shares in the capital of the Company, whether Domestic Shares or H Shares, and to make or grant offers, agreements and options in respect thereof, subject to the following conditions:
 - (a) such mandate shall not exceed beyond the Relevant Period save that the Board of Directors may during the Relevant Period make or grant offers, agreements, or options which might require the exercise of such powers after the end of the Relevant Period;
 - (b) the aggregate number of shares allotted or granted conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) by the Board of Directors shall not exceed:

LETTER FROM THE BOARD OF DIRECTORS

- (i) 20% of the aggregate number of Domestic Shares in issue as at the date of the passing of this resolution; and/or
 - (ii) 20% of the aggregate number of H Shares in issue as at the date of the passing of this resolution; and
- (c) the Board of Directors will only exercise its power under such mandate in accordance with the Company Law of the PRC and the Listing Rules (may be amended from time to time) and only if all necessary approvals from the China Securities Regulatory Commission and/or relevant PRC government authorities are obtained;

For the purpose of this resolution:

“Domestic Shares” means the ordinary shares issued by the Company in the PRC, with a nominal value of RMB1.00 each, which are subscribed for in RMB;

“H Shares” means the overseas-listed foreign invested shares in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in HKD;

“Relevant Period” means the period from the passing of the resolution until the earliest of:

- (A) the conclusion of the next annual general meeting of the Company following the passing of this resolution; or
 - (B) the expiration of the 12-month period following the passing of this resolution; or
 - (C) the date on which the authority set out in this resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting; and
- (2) subject to the Board of Directors resolving to issue shares pursuant to subparagraph (1) of this resolution, the Board of Directors be authorised to:
- (a) approve, execute and do or procure to be executed and done, all such documents, deeds and things as it may consider necessary in connection with the issue of such new shares including, without limitation determining, the time and place of issuance, making all necessary applications to the relevant authorities, entering into an underwriting agreement (or any other agreement);
 - (b) determine the use of proceeds and make all necessary filings and registrations with the relevant PRC, Hong Kong and other authorities; and

LETTER FROM THE BOARD OF DIRECTORS

- (c) increase the registered capital of the Company in accordance with the actual increase of capital by issuing shares pursuant to sub-paragraph (1) of this resolution, to register the increase of capital with the relevant authorities in the PRC and to make such amendments to the articles of association of the Company as it thinks fit so as to reflect the increase and any other changes in the registered capital of the Company.

III. AGM AND VOTING METHOD

A notice convening the AGM of the Company to be held at the meeting room of the Company, No. 38 Binjiang Road, Yidu, Yichang, Hubei Province, the PRC, at 10:00 a.m. on Friday, 8 June 2018, is set out on pages 13 to 18 of this circular. A form of proxy for use at the AGM is also enclosed. Such form of proxy is also published on the websites of the Stock Exchange and the Company.

Whether or not you intend to attend the AGM, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return the same to the Company's Board office at Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang'an County, Dongguan, Guangdong Province, the PRC (for holders of Domestic Shares) or to the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares). In any event, such form of proxy must be returned no later than 24 hours before the time appointed for the AGM (i.e. before 10:00 a.m. on Thursday, 7 June 2018) or any adjournment thereof. Completion and return of the form of proxy shall not preclude you from attending, and voting in person at the AGM or any adjournment thereof if you so desire.

Shareholders intending to attend the AGM (or any adjournment thereof) should complete and return the reply slip for attending the AGM (or any adjournment thereof) personally, by facsimile or by post. The reply slip should be completed and returned to the Company's Board office by facsimile (fax number: 86-769-81768866) or by post to (or by depositing it at) Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang'an County, Dongguan, Guangdong Province, the PRC, for holders of Domestic Shares; or to the Company's H share registrar in Hong Kong by facsimile (fax number: 852-2865-0990) or by post to (or by depositing it at) 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for holders of H Shares, such that the reply slip shall be received by the Company 20 days before the AGM (i.e. on or before Saturday, 19 May 2018).

Pursuant to rule 13.39(4) of the Listing Rules, any vote of shareholders at a general meeting must be taken by poll. Therefore, all the resolutions set out in the notice of the AGM shall be voted by poll. Voting by the Shareholders may be given either personally or by proxy.

LETTER FROM THE BOARD OF DIRECTORS

IV. CLOSURE OF REGISTER OF MEMBERS

In order to ascertain Shareholders' entitlement to attend and vote at the AGM and to the proposed 2017 Final Dividend, the register of members of the Company will be closed from Tuesday, 8 May 2018 to Friday, 8 June 2018 (both days inclusive) and from Thursday, 14 June 2018 to Tuesday, 19 June 2018 (both days inclusive) respectively, during which no transfer of Shares will be registered.

In order to qualify for attending and voting at the forthcoming AGM, all unregistered shareholders of the Company shall lodge transfer documents with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration before 4:30 p.m. on Monday, 7 May 2018.

In order to qualify for receiving the proposed 2017 Final Dividend (subject to the approval by the Shareholders at the AGM), unregistered shareholders of the Company shall lodge transfer documents with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at the above mentioned address for registration before 4:30 p.m. on Wednesday, 13 June 2018.

V. RECOMMENDATION

The Board of Directors considers that the above-mentioned resolutions are in the interests of the Company and the Shareholders as a whole, and thereby recommends the Shareholders to vote in favour of the resolutions at the AGM.

On behalf of the Board of Directors
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

NOTICE OF ANNUAL GENERAL MEETING



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 01558)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2017 annual general meeting (the “**AGM**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) will be held at the meeting room of the Company, No. 38 Binjiang Road, Yidu, Yichang, Hubei Province, the PRC, at 10:00 a.m. on Friday, 8 June 2018 to consider and, if thought fit, to pass the following resolutions:

ORDINARY RESOLUTIONS

1. To review and approve the report of the board of directors of the Company (the “**Board of Directors**”) for the year ended 31 December 2017.
2. To review and approve the report of the board of supervisors of the Company (the “**Board of Supervisors**”) for the year ended 31 December 2017.
3. To review and approve the consolidated financial statements of the Company for the year ended 31 December 2017.
4. To review and approve the 2017 annual report of the Company.
5. To review and approve the profit distribution plan and the declaration of final dividends of the Company for the year ended 31 December 2017.
6. To review and approve the re-appointment of KPMG as auditor of the Company for a term until the conclusion of the next annual general meeting of the Company, and authorize the Board of Directors to determine its remuneration.
7. To review and approve the election of Mr. JIANG Juncai as an executive director for the second session of the Board of Directors.
8. To review and approve the election of Mr. WANG Danjin as an executive director for the second session of the Board of Directors.
9. To review and approve the election of Mr. CHEN Yangui as an executive director for the second session of the Board of Directors.

NOTICE OF ANNUAL GENERAL MEETING

10. To review and approve the election of Mr. ZHU Qiaohong as an executive director for the second session of the Board of Directors.
11. To review and approve the election of Mr. LI Shuang as an executive director for the second session of the Board of Directors.
12. To review and approve the election of Mr. TANG Xinfu as a non-executive director for the second session of the Board of Directors.
13. To review and approve the election of Mr. TANG Jianxin as an independent non-executive director for the second session of the Board of Directors.
14. To review and approve the election of Mr. FU Hailiang as an independent non-executive director for the second session of the Board of Directors.
15. To review and approve the election of Mr. LEE Chi Ming as an independent non-executive director for the second session of the Board of Directors.
16. To review and approve the election of Ms. HUANG Fangfang as a shareholder representative supervisor for the second session of the Board of Supervisors.
17. To review and approve the election of Mr. LUO Zhonghua as a shareholder representative supervisor for the second session of the Board of Supervisors.

SPECIAL RESOLUTION

18. To review and approve the following:

“THAT:

- (1) the Board of Directors be granted an unconditional general mandate to allot, issue and deal with additional shares in the capital of the Company, whether domestic shares or H shares, and to make or grant offers, agreements and options in respect thereof, subject to the following conditions:
 - (a) such mandate shall not exceed beyond the Relevant Period save that the Board of Directors may during the Relevant Period make or grant offers, agreements, or options which might require the exercise of such powers after the end of the Relevant Period;

NOTICE OF ANNUAL GENERAL MEETING

- (b) the aggregate amount of shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) by the Board of Directors shall not exceed:
 - (i) 20 per cent of the aggregate number of Domestic Shares in issue as of the passing date of this resolution; and/or
 - (ii) 20 per cent of the aggregate number of H Shares in issue as of the passing date of this resolution; and
- (c) the Board of Directors will only exercise its power under such mandate in accordance with the Company Law of the People's Republic of China (the "**PRC**") and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") (may be amended from time to time) and only if all necessary approvals from the China Securities Regulatory Commission and/or other relevant PRC government authorities are obtained;

For the purpose of this resolution:

"Domestic Shares" means ordinary shares issued by the Company in the PRC, with a nominal value of RMB1.00 each, which are subscribed for in Renminbi ("**RMB**");

"H Shares" means the overseas-listed foreign invested shares in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong Dollars;

"Relevant Period" means the period from the passing of this resolution until the earliest of:

- (A) the conclusion of the next annual general meeting of the Company following the passing of this resolution; or
- (B) the expiration of the 12-month period following the passing of this resolution; or
- (C) the date on which the authority set out in this resolution is revoked or varied by a special resolution of the shareholders of the Company in a general meeting; and

NOTICE OF ANNUAL GENERAL MEETING

- (2) subject to the Board of Directors resolving to issue shares pursuant to sub-paragraph (1) of this resolution, the Board of Directors be authorized to:
- (a) approve, execute and do or procure to be executed and done, all such documents, deeds and things as it may consider necessary in connection with the issue of such new shares including, without limitation, determining the time and place of issue, making all necessary applications to the relevant authorities, and entering into an underwriting agreement (or any other agreements);
 - (b) determine the use of proceeds and to make all necessary filings and registrations with the relevant PRC, Hong Kong and other authorities; and
 - (c) increase the registered capital of the Company in accordance with the actual increase of capital by issuing shares pursuant to sub-paragraph (1) of this resolution, to register the increase of capital with the relevant authorities in the PRC and to make such amendments to the Articles of Association of the Company as it thinks fit so as to reflect the increase and any other resultant changes in the registered capital of the Company.”

On behalf of the Board of Directors
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC, 23 April 2018

Notes:

1. In order to determine the list of shareholders who will be entitled to attend and vote at the AGM, the registers of members of the Company will be closed from Tuesday, 8 May 2018 to Friday, 8 June 2018, both days inclusive, during which period no transfer of shares will be effected. Shareholders whose names appear on the registers of members of the Company on Tuesday, 8 May 2018 shall be entitled to attend and vote at the AGM. In order for the shareholders to qualify to attend and vote at the AGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Board office at Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang’an County, Dongguan, Guangdong Province, the PRC, for holders of domestic shares, or the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, for holders of H shares no later than 4:30 p.m. on Monday, 7 May 2018 for registration.

NOTICE OF ANNUAL GENERAL MEETING

2. In order to ascertain shareholders' entitlement to the proposed 2017 final dividend, the register of members of the Company will be closed from Thursday, 14 June 2018 to Tuesday, 19 June 2018 (both days inclusive), during which no transfer of shares will be registered. Shareholders whose names appear on the registers of members of the Company on Tuesday, 19 June 2018 shall be entitled to receive the proposed 2017 final dividend (subject to the approval by the shareholders of the Company at the forthcoming AGM). In order to qualify for receiving the proposed 2017 final dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Board office at Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang'an County, Dongguan, Guangdong Province, the PRC, for holders of domestic shares, or the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for holders of H shares no later than 4:30 p.m. on Wednesday, 13 June 2018. The proposed 2017 final dividend is expected to be paid on or around 16 July 2018 if being approved by the shareholders of the Company at the forthcoming AGM.
3. Shareholders intending to attend the AGM (or any adjournment thereof) should complete and return the reply slip for attending the AGM (or any adjournment thereof) personally, by facsimile or by post. The reply slip should be completed and returned to the Company's Board office by facsimile (fax number: 86-769-81768866) or by post to (or by depositing it at) Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang'an County, Dongguan, Guangdong Province, the PRC, for holders of domestic shares; or to the Company's H share registrar in Hong Kong by facsimile (fax number: 852-2865-0990) or by post to (or by depositing it at) 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for holders of H shares, such that the reply slip shall be received by the Company 20 days before the AGM (i.e. on or before Saturday, 19 May 2018).
4. Shareholders may, by completing the form of proxy of the Company, appoint one or more proxies to attend and vote at the AGM (or any adjournment thereof) on his behalf. A proxy need not be a shareholder of the Company.
5. Shareholders must use the form of proxy of the Company for appointing a proxy and the appointment must be in writing. The form of proxy must be signed by the relevant shareholder of the Company or by a person duly authorized by the relevant shareholder of the Company in writing ("**power of attorney**"). If the form of proxy is signed by the person authorized by the relevant shareholder of the Company as aforesaid, the relevant power of attorney and other relevant documents of authorization (if any) must be notarized. If a corporate shareholder of the Company appoints a person other than its legal representative to attend the AGM (or any adjournment thereof) on its behalf, the relevant form of proxy must be affixed with the company seal of the corporate shareholder of the Company or duly signed by its director or any other person duly authorized by that corporate shareholder of the Company as required by the articles of association of such company.
6. To be valid, the form of proxy and the relevant notarized power of attorney (if any) and other relevant documents of authorization (if any) as mentioned in note 5 above must be delivered to the Company's Board office at Securities Department, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang'an County, Dongguan, Guangdong Province, the PRC for holders of domestic shares, or the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for holders of H shares not less than 24 hours before the time appointed for the AGM (or any adjournment thereof) (i.e. before 10:00 a.m. on Thursday, 7 June 2018).
7. A shareholder of the Company or his proxy should produce proof of identity when attending the AGM (or any adjournment thereof). If a corporate shareholder's legal representative or any other person duly authorized by such corporate shareholder of the Company attends the AGM (or any adjournment thereof), such legal representative or other person shall produce his proof of identity, and proof of designation as legal representative or the valid authorization document (as the case may be).

NOTICE OF ANNUAL GENERAL MEETING

8. The AGM (or any adjournment thereof) is expected to last less than one day. Shareholders or their proxies who attend the AGM (or any adjournment thereof) shall bear their own travelling, meal and accommodation expenses.
9. The Company's principal place of business in the PRC is situated at:
- No. 38 Binjiang Road, Yidu, Yichang, Hubei Province, the PRC
Tel No.: 86-769-81768886
Fax No.: 86-769-81768866
- The address of the Company's H share registrar, Computershare Hong Kong Investor Services Limited is:
- Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
Tel No.: 852-2862-8555
Fax No.: 852-2865-0990
10. Pursuant to rule 13.39(4) of the Listing Rules, any vote of shareholders at a general meeting must be taken by poll except where the chairman of the general meeting, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands.

As at the date of this notice, the executive directors of the Company are Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. ZHU Qiaohong; the non-executive directors are Mr. TANG Xinfu and Mr. MO Kit; and the independent non-executive directors are Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming.

Biographical details of the candidates for Directors of the second session of the Board of Directors are set out below:

Candidates for Executive Directors

Mr. JIANG Juncai (蔣均才), aged 36, is an executive Director and the general manager of the Company. He joined the Company in May 2015 and has served as an executive Director since then.

Mr. Jiang has also served as a director of Yidu HEC Industrial Development Co., Ltd. from March 2012 to May 2015. Prior to that, Mr. Jiang was a director of Yichang Shancheng Cordyceps Sinensis Co., Ltd. (宜昌山城水都冬蟲夏草有限公司) from March 2012 to July 2015, and successively served as a researcher at the biochemistry division, a researcher and deputy head of the traditional Chinese medicine division and the deputy head of the zoological and botanical division of Sunshine Lake Pharma Co., Ltd. from July 2006 to May 2012.

Mr. Jiang graduated with a master degree in science from Shenyang Pharmaceutical University in June 2006.

Mr. WANG Danjin (王丹津), aged 48, is an executive Director and a deputy general manager of the Company. He joined the Company in February 2006, and has served as an executive Director since then.

Mr. Wang has also served as a supervisor of HEC Pharm Co., Ltd. (the “**Parent Company**”) from December 2010 to July 2015, and a director of Yichang HEC Pharmaceutical Co., Ltd. from April 2006 to January 2018. Prior to joining the Company, Mr. Wang was the head of production department of Jilin Tonghua Dongri Pharmaceutical Joint Stock Co., Ltd. (吉林省通化東日藥業股份有限公司) from March 2002 to January 2006, and a technologist at Jilin Dandong Pharmaceutical Factory (吉林省丹東製藥廠) from November 1991 to February 2002.

Mr. Wang graduated with a bachelor degree from Shenyang Pharmaceutical University (瀋陽藥科大學) through correspondence courses in January 2008. He is recognised as a licensed pharmacist by Ministry of Human Resources and Social Security of the People’s Republic of China (formerly known as Ministry of Personnel of the People’s Republic of China), and was recognised as a pharmacist-in-charge by Bureau of Human Resources and Social Security of Dandong (formerly known as Bureau of Personnel of Dandong (丹東市人事局)) in October 2001.

Mr. CHEN Yangui (陳燕桂), aged 36, is an executive Director. He joined the Company in May 2014, serving as the head of the sales department. Mr. Chen has served as an executive Director since May 2015. Mr. Chen has also served as a general manager of Yichang HEC Pharmaceutical Co., Ltd. since March 2016, a supervisor of Ruyuan HEC Medical Instrument Co., Ltd. (乳源東陽光醫療器械有限公司) since July 2012 and a director of Ruyuan HEC

Pharmaceutical Co., Ltd. since February 2010. Mr. Chen joined Dongguan HEC Medicine Development and Research Co., Ltd. in 2005, and successively held positions as a researcher, the deputy head of research and development department and the head of synthesis department before he was appointed as the deputy head of research institute and the head of generic drug department.

Mr. Chen graduated with a master degree in science from Hunan University in June 2006.

Mr. ZHU Qiaohong (朱巧洪), aged 49, is an executive Director and the deputy general manager of the Company. He joined the Company in May 2002, and has served as the deputy general manager of the Company since then, and served as an executive Director of the Company since June 2017.

Mr. ZHU Qiaohong has also been the vice chairman of Pharmaceutical Profession Association of Hubei Province since April 2015, and has served as a supervisor of Yichang HEC Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of the Company) since June 2005. Prior to that, Mr. ZHU Qiaohong was the director of GMP office of Apelo Kangyu Pharmaceutical Co., Ltd. from October 1993 to May 2002, and a technician of the General Security Station of the State-owned Ecological Forest (國有生態公益林業保護總站) of Dongyang City from August 1990 to October 1993. Moreover, Mr. Zhu graduated with a bachelor degree in science from Jilin University in July 1990. He was recognised as an engineer in pharmaceutical engineering by the Bureau of Human Resources and Social Security of Jinhua (formerly known as the Bureau of Personnel of Jinhua (金華市人事局)) in August 1999.

Mr. LI Shuang (李爽), aged 37, is the deputy general manager of the Company. He joined the Company in August 2005 and worked as a member of the insulin research team. He has served as the deputy general manager of the Company since May 2015.

Mr. Li has also served as the deputy head of the Company's insulin factory since October 2013 and the head of API department of that factory since February 2006. Mr. Li was the head of purification department of the Company's insulin factory from December 2008 to September 2013.

Mr. Li graduated with a bachelor degree in engineering from China Three Gorge University (三峽大學) in June 2004.

Candidates for Non-executive Director

Mr. TANG Xinfa (唐新發), aged 48, is the chairman and a non-executive Director of the Board. He joined the Company in May 2015 and has served as a non-executive Director since then.

Name of Company/Entity	Positions/material commitment	Principal Duty	Period
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.	Legal representative and director	Corporate management and decision-making	Since January 2017
Shenzhen HEC Pharmaceutical Co., Ltd.	Director	Corporate management and decision-making	Since March 2016
Linzhi HEC Pharmaceutical Research Co., Ltd.	Legal representative and director	Corporate management and decision-making	Since December 2016
Shenzhen HEC Industrial Development Co., Ltd.	Director and general manager	Corporate management and decision-making	Since November 2015
Yichang HEC Research Co., Ltd.	Legal representative, executive director and general manager	Corporate management and decision-making	Since December 2014
Yichang HEC Pharm Co., Ltd.	Vice chairman, executive director and deputy general manager	Corporate management and decision-making	Since March 2011
Dongguan HEC Medicine Development and Research Co., Ltd.	Legal representative and executive director	Corporate management and decision-making	Since October 2010
Linzhi HEC Pharmaceutical Investment Co., Ltd.	Director	Corporate management and decision-making	Since May 2010
Ruyuan HEC Pharmaceutical Co., Ltd.	Director	Corporate management and decision-making	Since September 2009
Sunshine Lake Pharma Co., Ltd.	Director	Corporate management and decision-making	Since September 2005

Name of Company/Entity	Positions/material commitment	Principal Duty	Period
Dongguan HEC Industrial Development Co., Ltd.	Legal representative and director	Corporate management and decision-making	Since December 2004
Shenzhen HEC Industrial Development Co., Ltd.	Chief of the office	Corporate management and decision-making	Since September 2002 to September 2005

Mr. Tang received a master degree in literary aesthetics from the Department of Chinese of Xiamen University in September 2002.

Candidates for Independent Non-executive Directors

Mr. TANG Jianxin (唐建新), aged 53, was appointed as an independent non-executive Director in May 2015.

Mr. Tang has also served as an independent director of Sino Great Wall Co., Ltd. (SZSE Stock Exchange stock number: 000018) since December 2015, an independent director of Pingdingshan Tianan Coal Mining Co., Ltd. (SSE stock code: 601666) since May 2013, an independent director of Zhongbai Holdings Group Co., Ltd. (SZSE stock code: 000759) from December 2011 to December 2017, an independent director of Shenzhen Huapengfei Modern Logistics Co., Ltd. (SZSE stock code: 300350) from August 2010 to August 2016, an independent director of Wuhan Sanzhen Industry Holding Co., Ltd. (SSE stock code: 600168) from June 2009 to June 2015, and an independent director of Wuhan Zhongnan Commercial (Group) Co., Ltd. (SZSE stock code: 000785) from May 2008 to May 2014. Prior to that, Mr. Tang served as an independent director of Wuhan Accelink Technologies Co., Ltd. (SZSE stock code: 002281) from September 2006 to September 2009 and an independent director of Hubei Chutian Expressway Co., Ltd (湖北楚天高速公路股份有限公司) (SSE stock code: 600035) from April 2002 to April 2008. Mr. Tang has been the professor of Accounting Department of Economics and Management School at Wuhan University since 2006 and has been a doctoral tutor of Accounting Department at Wuhan University since 2006. He served as the dean of Accounting Department of Economics and Management School in the same university from 2005 to 2015. He has been a professor at Wuhan University since 2004, and worked for the postdoctoral research center of the accounting department of Renmin University of China from 2000 to 2002.

Mr. Tang received his bachelor degree from the Economics Department of Wuhan University in June 1985, and then obtained a master degree in economics and a doctoral degree in economics from Wuhan University in September 1988 and January 1999 respectively. Mr. Tang was granted independent auditor qualifications by the National Audit Office of the People's Republic of China in December 1992, and CPA qualification by the China Institute of Certified Public Accountants in December 1997.

Mr. FU Hailiang (付海亮), aged 46, was appointed as an independent non-executive Director in May 2015.

Mr. Fu has been a partner and the head of administration function of Hubei S&H Law Firm since May 2005. He was a partner of Hubei Haohan Law Firm (湖北浩瀚律師事務所) from October 2000 to May 2005 and an associate at Wuhan Third Law Firm (武漢市第三律師事務所) from November 1996 to October 2000. Mr. Fu has been a council member of the Wuhan Lawyers Association and the chief of the Association of Finance, Securities and Law Industry (金融證券法律專業委員會) since February 2014.

Mr. Fu graduated with a professional certification in financial management from Wuhan University in July 1993, and graduated with a bachelor degree in law from Zhongnan University of Economics and Law in June 1998. After that, he graduated with a master degree in law from Wuhan University in February 2003. Mr. Fu has been admitted to practice PRC law in June 1998 and was recognized as an excellent lawyer of Hubei by the Department of Justice of Hubei and the Hubei Lawyers Association (湖北省律師協會) in March 2011.

Mr. LEE Chi Ming (李志明), aged 64, was appointed as an independent non-executive Director in May 2015.

Mr. Lee has also served as a director of Ever East Consultants Limited in Hong Kong since August 2013 and served as a director of Knowledge Transfer, Office of Research and Knowledge Transfer Services in the Chinese University of Hong Kong since September 2016. Prior to that, Mr. Lee served as an executive science director in the research of central nervous system and pain control and a global product director of AstraZeneca Pharmaceuticals Co. Ltd., a section head, associate director and project manager at Bayer Corporation and a senior group leader of neuroscience at Abbott Laboratories. He also worked as a lecturer and then a senior lecturer at the Chinese University of Hong Kong from September 1982 to February 1992.

Mr. Lee received a bachelor degree in science and a master degree in biochemistry from the University of Hong Kong in June 1975 and July 1977 respectively, and a doctoral degree in pharmacology from the University of Cambridge in July 1980 before he completed his postdoctoral research at the Johns Hopkins University in July 1982.

Biographical details of the candidates for shareholder representative Supervisors and the employee representative Supervisors for the second session of the Board of Supervisors are set out below:

Ms. HUANG Fangfang (黃芳芳), aged 36, is a Supervisor of the Company. She joined the Company in May 2015, and has been the chairman of the Board of Supervisors since then. She has also served as the executive deputy head of the generic drug department of Sunshine Lake Pharma Co., Ltd. since June 2014, and the head of formulation department of Sunshine Lake Pharma Co., Ltd. since February 2009. Prior to that, Ms. Huang was the head of analysis section under the formulation department of Sunshine Lake Pharma Co., Ltd. from July 2006 to February 2009, the head of formulation department of Sunshine Lake Pharma Co., Ltd. since February 2009, and the executive deputy head of the generic drug department of Sunshine Lake Pharma Co., Ltd. since June 2014.

Ms. Huang graduated with a master degree in science from Sun Yat-sen University in June 2006.

Mr. LUO Zhonghua (羅忠華), aged 34, is a Supervisor of the Company. He joined Dongguan HEC Medicine Development and Research Co., Ltd. (東莞東陽光藥研發有限公司) (a subsidiary of Shenzhen HEC Industrial Development Co., Ltd. (深圳市東陽光實業發展有限公司), the controlling shareholder of the Company) since June 2005 to engage in the research and development of APIs. He is currently the head of the generic drug API synthesis department and deputy head of the generic drug division in Dongguan HEC Development and Research Co., Ltd.

Mr. LUO Zhonghua graduated from the Central South University in June 2005 with a bachelor's degree in pharmaceutical engineering and Sun Yat-sen University in 2015 with a master's degree in pharmaceutical analysis, respectively.

Mr. WANG Shengchao (王勝超), aged 35, is an employee representative Supervisor and the deputy chief of the quality division of the Company. He joined the Company in May 2012 as a quality controller of the quality division, and served as the vice director of quality assurance of the quality division of the Company from April 2015. Mr. Wang held the position of the quality assurance director of the quality division of the Company from May 2016 to June 2017, and served as the deputy chief of the quality division of the Company from July 2017.

Prior to joining the Company, Mr. Wang worked as a researcher of new traditional Chinese medicines in Hebei Yiling Pharmaceutical Group (河北以嶺醫藥集團) from July 2008 to March 2010, a pharmaceutical analysis researcher in Pharmaron (Beijing) New Medicines Technology Co., Ltd. (康龍化成(北京)新藥技術有限公司) from April 2010 to May 2011, and an inspection engineer and inspection supervisor of the quality department in Lepu (Beijing) Medical Equipment Co., Ltd. (樂普(北京)醫療器械股份有限公司) from June 2011 to May 2012. Mr. Wang graduated with a master degree in science from Shenyang Pharmaceutical University in July 2008.